Archive · 23 Jul 2026
Eli Lilly's Retatrutide Clears Heart Risk Hurdle
Eli Lilly, a big pharmaceutical company, has a new weight-loss drug called retatrutide.
They did a study to check if it's safe for the heart, and it looks good.
This drug is special because it combines three different gut hormones, which makes it more effective than other weight-loss drugs.
Lilly wants to sell it as a biologic medicine, which would give them more protection and time before the government cuts prices.
They are waiting to ask the FDA for approval until early next year.
Some people are even trying to get black-market versions of the drug because it's so promising.
Eli Lilly's retatrutide showed no increased overall heart risk in a new study.
The drug combines three gut hormones, making it more effective than current treatments.
Lilly plans to file for FDA approval early next year, later than initially expected.
The company is seeking biologic classification for retatrutide to extend its market exclusivity.
Analysts predict nearly $16 billion in sales by 2036 if approved.
- Who
- Eli Lilly & Co.
- What
- Retatrutide, a next-generation weight-loss drug, cleared a cardiovascular safety hurdle in a new study.
- When
- The findings were announced on Thursday, with FDA approval expected early next year.
- Where
- The study and regulatory process are primarily focused in the United States.
- Why
- To address concerns over heart risk and solidify the drug's blockbuster potential.
Biologic Classification
Conventional Drug Classification
Regulatory Pathway
Biologic Classification
Lilly argues that retatrutide should be classified as a biologic due to its 39 amino acids and a side chain, which they believe meets the federal requirement of more than 40 amino acids.
Conventional Drug Classification
The FDA interprets the rule narrowly, potentially classifying retatrutide as a conventional drug.
- Company
- Eli Lilly & Co.
- Drug Name
- Retatrutide
- Approval Pathway
- Biologics License Application (BLA)
- Expected FDA Filing
- Early 2027
- Potential Sales by 2036
- $16 billion
- Current Market Leader
- Zepbound
- Competitor
- Novo Nordisk A/S